Equities research analysts expect that Accuray Incorporated (NASDAQ:ARAY) will announce earnings of ($0.01) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Accuray’s earnings. Accuray also posted earnings per share of ($0.01) during the same quarter last year. The business is expected to announce its next quarterly earnings results after the market closes on Wednesday, August 11th.
According to Zacks, analysts expect that Accuray will report full-year earnings of $0.03 per share for the current year, with EPS estimates ranging from $0.01 to $0.04. For the next year, analysts forecast that the company will report earnings of $0.08 per share, with EPS estimates ranging from $0.02 to $0.11. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Accuray.
Separately, Zacks Investment Research lowered Accuray from a “hold” rating to a “sell” rating and set a $5.00 price target on the stock. in a research report on Thursday, April 29th.
NASDAQ:ARAY traded down $0.04 during trading hours on Friday, hitting $4.14. 400 shares of the company’s stock traded hands, compared to its average volume of 477,960. The stock has a market cap of $386.10 million, a price-to-earnings ratio of 103.53 and a beta of 1.87. Accuray has a twelve month low of $2.17 and a twelve month high of $6.01. The company has a debt-to-equity ratio of 2.09, a quick ratio of 1.15 and a current ratio of 1.86. The stock has a fifty day moving average price of $4.40.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Recommended Story: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.